Gilead Sciences, Inc.

- Gilead does not expect to pursue any sizable M&A transactions in the near term, indicating no major immediate fundraising through debt or equity. - The company has about $5 billion in cash and leverage levels back to pre-Immunomedics deal, suggesting a strong balance sheet. - In the near term, Gilead plans to continue ordinary course licensing deals but no meaningful M&A. - The company remains disciplined in capital allocation with flexibility to invest in the pipeline. - Earnings call statements highlight confidence in managing expenses and operating margin improvement without mentioning imminent new fundraising efforts.

- Gilead plans to double its manufacturing capacity for cell therapies, reflecting strategic investment in expanding production capabilities. - The company is investing incrementally to support the launch of seladelpar as well as other R&D efforts; these investments are managed within their previously issued guidance. - Gilead intends to advance next-generation CAR-T lymphoma assets quickly, supported by in-house vector and construct creation capabilities. - Focus remains on disciplined capital allocation with flexibility; near term, Gilead does not expect sizable M&A but will continue with ordinary course business development and smaller licensing deals. - The CymaBay acquisition included investments anticipated to be breakeven by 2025 and accretive thereafter. - Operating expenses include incremental costs related to CymaBay but remain within disciplined expense management approaches to facilitate operating margin expansion over time.

- **2024 Revenue Guidance:** Total product sales expected between $27.1 to $27.5 billion, excluding Veklury sales of about $1.3 billion. Base business sales projected to grow 4% to 6% year-over-year. - **HIV Franchise:** HIV sales projected to grow 4% in 2024; however, HIV sales expected to be roughly flat in 2025 due to Medicare Part D redesign impact. Overall, total business expected to grow in 2025 despite HIV headwind. - **Trodelvy:** Continuing strong growth with sales exceeding $1 billion annually; multiple Phase 3 trials underway targeting new indications and earlier lines of therapy, expected to drive future revenue growth. - **Seladelpar (CymaBay acquisition):** Expected modest revenue contribution in 2024 after regulatory approval; anticipated meaningful growth in 2025 and beyond. - **Cell Therapy (Kite):** Expansion plans to grow authorized treatment centers and launch novel therapies, contributing to growth. - **Operating Margin:** Expected improvement with disciplined expense management supporting revenue growth.

- For 2024, Gilead expects total product sales between $27.1 to $27.5 billion, with base business growth of 4% to 6% year over year excluding Veklury. - Gross margin guidance remains unchanged; product gross margins expected stable. - R&D expenses anticipated to grow at the higher end of low-to-mid single-digit range due to CymaBay acquisition and milestones. - SG&A expenses expected modestly higher due to CymaBay but managed within overall operating expense guidance. - Acquired IPR&D charges projected around $4.4 billion, increasing total operating expenses to $7-7.5 billion. - Effective tax rate in 2024 is ~30%, factoring in nondeductible CymaBay acquisition charges. - Diluted EPS guidance for 2024 is $3.45 to $3.85; excluding charges, comfortably within previous guidance. - EPS expected to be breakeven with CymaBay deal in 2025 and significantly accretive thereafter. - Operating margin expected to improve over time due to disciplined expense management and topline growth.

The provided transcript pages do not explicitly mention details on Gilead Sciences' current or expected orderbook or pending orders. However, relevant insights related to business outlook and sales include: - Total product sales (excluding Veklury) grew 6% year-over-year to $6.1 billion in Q1 2024. - HIV sales up 4% year-over-year to $4.3 billion, driven by demand and favorable pricing. - Oncology sales increased 18% year-over-year. - Liver disease sales up 9%, supported by portfolio demand. - Veklury sales down 3% year-over-year due to reduced COVID-19 hospitalizations. - Expectation of approximately 4% HIV sales growth for 2024. - CymaBay acquisition product seladelpar expected to contribute modestly in 2024 and more significantly in 2025 and beyond. - No explicit mention of orderbook or pending orders; focus is on ongoing demand and growth outlook. No direct data on orderbook or pending orders is available in the text.